These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3030776)

  • 21. Genotype-dependent behavioral sensitivity to mu vs. kappa opiate agonists. I. Acute and chronic effects on mouse locomotor activity.
    Gwynn GJ; Domino EF
    J Pharmacol Exp Ther; 1984 Nov; 231(2):306-11. PubMed ID: 6092613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential tolerance and cross-tolerance to chronic treatment with mu and kappa opioid agonists in the rat.
    Young GA; Khazan N
    NIDA Res Monogr; 1984 Mar; 49():121-7. PubMed ID: 6090915
    [No Abstract]   [Full Text] [Related]  

  • 23. Tripelennamine: enhancement of brain-stimulation reward.
    Unterwald EM; Kucharski LT; Williams JE; Kornetsky C
    Life Sci; 1984 Jan; 34(2):149-53. PubMed ID: 6607395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of morphine in rats treated chronically with U-50,488 H, a kappa opioid receptor agonist.
    Bhargava HN; Ramarao P; Gulati A
    Eur J Pharmacol; 1989 Mar; 162(2):257-64. PubMed ID: 2542058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma corticosterone changes in response to central or peripheral administration of kappa and sigma opiate agonists.
    Eisenberg RM
    J Pharmacol Exp Ther; 1985 Jun; 233(3):863-9. PubMed ID: 2989500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus.
    Katsidoni V; Anagnostou I; Panagis G
    Addict Biol; 2013 Mar; 18(2):286-96. PubMed ID: 22862835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The interaction of eptazocine, a novel analgesic, with opioid receptors.
    Nabeshima T; Matsuno K; Kamei H; Kameyama T
    Res Commun Chem Pathol Pharmacol; 1985 May; 48(2):173-81. PubMed ID: 2992058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies of kappa agonist.
    Kumor K; Su TP; Vaupel B; Haertzen C; Johnson RE; Goldberg S
    NIDA Res Monogr; 1986; 67():18-25. PubMed ID: 3018572
    [No Abstract]   [Full Text] [Related]  

  • 29. Central cardiovascular effects of kappa agonists dynorphin-(1-13) and ethylketocyclazocine in the anaesthetized rat.
    Laurent S; Schmitt H
    Eur J Pharmacol; 1983 Dec; 96(1-2):165-9. PubMed ID: 6319158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phencyclidine-induced stereotyped behaviors after injection of ethylketocyclazocine, Mr 2266 and naltrexone in rats.
    Nabeshima T; Hiramatsu M; Kameyama T
    Brain Res; 1986 Jul; 378(2):234-9. PubMed ID: 3015356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-related effects of ethylketazocine on nociception, behaviour and autonomic responses in the horse.
    Kamerling SG; Dequick DJ; Weckman TJ; Tobin T
    J Pharm Pharmacol; 1986 Jan; 38(1):40-5. PubMed ID: 2869125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (+)-[3H]SKF 10,047, (+)-[3H]ethylketocyclazocine, mu, kappa, delta and phencyclidine binding sites in guinea pig brain membranes.
    Tam SW
    Eur J Pharmacol; 1985 Feb; 109(1):33-41. PubMed ID: 2986989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo.
    Kumor KM; Haertzen CA; Johnson RE; Kocher T; Jasinski D
    J Pharmacol Exp Ther; 1986 Sep; 238(3):960-8. PubMed ID: 3018228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic analgesic interactions between the periaqueductal gray and the locus coeruleus.
    Bodnar R; Paul D; Pasternak GW
    Brain Res; 1991 Sep; 558(2):224-30. PubMed ID: 1664270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurochemical actions of ethylketocyclazocine and ketocyclazocine in different regions of rat brain.
    Gavend MM; Serre-Debeauvais F; Gavend MR; Pastrello D; Caron F; Baragatti G
    Biomed Pharmacother; 1987; 41(7):400-6. PubMed ID: 3328633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medial forebrain stimulation enhances intracranial nociception and attenuates morphine analgesia suggesting the existence of an endogenous opioid antagonist.
    Kornetsky C; Knapp CM; Tozier L; Pak A
    Pharmacol Biochem Behav; 2010 May; 95(3):273-7. PubMed ID: 20149816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
    Picker MJ; Doty P; Negus SS; Mattox SR; Dykstra LA
    J Pharmacol Exp Ther; 1990 Jul; 254(1):13-22. PubMed ID: 2164087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medullary kappa hyperalgesic mechanisms II. The effects of ethylketazocine administered into the fourth cerebral ventricle of the conscious dog.
    Kamerling SG; Martin WR; Wu KM; Wettstein JG
    Life Sci; 1983 Oct; 33(18):1839-43. PubMed ID: 6139723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes.
    Rothman RB; France CP; Bykov V; De Costa BR; Jacobson AE; Woods JH; Rice KC
    Eur J Pharmacol; 1989 Aug; 167(3):345-53. PubMed ID: 2553442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac slowing induced by peripheral kappa-opiate receptor stimulation in rats.
    Gautret B; Schmitt H
    Eur J Pharmacol; 1984 Jun; 102(1):159-63. PubMed ID: 6148245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.